Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 2:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional Results available

Hp129 Xenon Imaging and BOS in Lung Transplantation

NCT03603899
Conditions
Bronchiolitis Obliterans
Interventions
Hp 129Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Lung Transplant Rejection
Interventions
Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Assessing Pulmonary Changes in HSCT

NCT07823036
Conditions
HSCT, Respiratory, Gas Exchange Impairment
Interventions
Hyperpolarized 129 Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years and older
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 2 Interventional Results available

Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

NCT04071769
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer
Drug · Device
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Hyperpolarized Xenon-129 MR Imaging of the Lung

NCT04662658
Conditions
E-Cig Use
Interventions
Hyperpolarized Xenon -129 MRI
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults

NCT02272049
Conditions
Respiratory Disorders
Interventions
Hyperpolarized 129 Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology

NCT06856525
Conditions
Electronic Cigarette Related Lung Damage
Interventions
Hyperpolarized xenon 129, Cardiopulmonary Stress Test, Pulmonary Function Test, Chest CT
Drug · Diagnostic Test
Lead sponsor
Y. Michael Shim, MD
Other
Eligibility
18 Years to 35 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration

NCT02316379
Conditions
Respiratory Disorders
Interventions
Hyperpolarized 129 Xenon, MRI
Drug · Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2032
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Lungs; Developmental Disorder
Interventions
129Xe
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 6 Months
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

NCT04467957
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator, Hyperpolarized Xenon 129
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Withdrawn Phase 1 Interventional Accepts healthy volunteers

129Xe MRI in Pediatric Population With BPD

NCT04035629
Conditions
Bronchopulmonary Dysplasia
Interventions
MagniXene, hyperpolarized 129Xe MRI
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
Up to 1 Year
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Radiation Injury
Interventions
Hyperpolarized 129-Xenon gas, MRI
Drug · Device
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Active, not recruiting Phase 2 Interventional

Xenon MRI and Progressive ILD

NCT05241275
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Severe Asthma, COPD, Non-CF Bronchiectasis, Cystic Fibrosis (CF)
Interventions
Hyperpolarized 129 Xenon
Combination Product
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized 129-Xenon gas, MRI
Drug · Device
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Madison, Wisconsin
Conditions
Severe Asthma
Interventions
Hyperpolarized Xenon 129
Combination Product
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Pulmonary, Pneumonia, Hematopoietic System--Cancer
Interventions
29-XeMRI imaging
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

NCT06012500
Conditions
ILD
Interventions
Xenon-129
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Enrolling by invitation Phase 1Phase 2 Interventional Accepts healthy volunteers

Technical Development of Xe MRI

NCT07823010
Conditions
HSCT, Lung Transplant Recipient
Interventions
Hyperpolarized 129 Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio